What question did this study set out to answer?

To review current knowledge on rare molecular variants of gastrointestinal stromal tumors (GISTs) and evaluate their clinical course, sensitivity to tyrosine kinase inhibitors, and alternative therapeutic strategies.

August 14, 2026Targeted OncologyOpen Access

Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence

View Full Paper

Ask AI

Bookmark

Authors

AKAnna Klimczak KKKatarzyna Kisielewska ASAnna Szumera‐Ciećkiewicz

Discussion

Member takes

Overview

Narrative review reveals therapeutic challenges of rare GIST variants, highlighting the need for comprehensive molecular profiling to guide targeted therapy.

Key Points

To review current knowledge on rare molecular variants of gastrointestinal stromal tumors (GISTs) and evaluate their clinical course, sensitivity to tyrosine kinase inhibitors, and alternative therapeutic strategies.
Synthesized clinical and translational literature evaluating canonical (KIT, PDGFRA) and rare non-canonical molecular alterations in gastrointestinal stromal tumors.
Evaluated mechanisms of primary and secondary resistance to standard tyrosine kinase inhibitor (TKI) regimens and reviewed emerging alternative therapeutic modalities.
Non-canonical and rare molecular alterations in GIST exhibit distinct pathogenic mechanisms that frequently confer primary or secondary resistance to standard tyrosine kinase inhibitors.
Comprehensive molecular characterization improves patient risk stratification and is essential for identifying actionable targets and guiding selection of alternative targeted regimens.

Cite This Study

Klimczak et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec746b70b84ec8b9137b3 https://doi.org/10.1007/s11523-026-01249-6

View Full Paper

Ask AI

Bookmark

August 14, 2026Targeted OncologyOpen Access

Rare Molecular Variants of Gastrointestinal Stromal Tumors (GISTs): Clinical Implications and Overview of Current Evidence

View Full Paper

Ask AI

Bookmark

Authors

AKAnna Klimczak KKKatarzyna Kisielewska ASAnna Szumera‐Ciećkiewicz

Discussion

Member takes

Overview

Narrative review reveals therapeutic challenges of rare GIST variants, highlighting the need for comprehensive molecular profiling to guide targeted therapy.

Key Points

To review current knowledge on rare molecular variants of gastrointestinal stromal tumors (GISTs) and evaluate their clinical course, sensitivity to tyrosine kinase inhibitors, and alternative therapeutic strategies.
Synthesized clinical and translational literature evaluating canonical (KIT, PDGFRA) and rare non-canonical molecular alterations in gastrointestinal stromal tumors.
Evaluated mechanisms of primary and secondary resistance to standard tyrosine kinase inhibitor (TKI) regimens and reviewed emerging alternative therapeutic modalities.
Non-canonical and rare molecular alterations in GIST exhibit distinct pathogenic mechanisms that frequently confer primary or secondary resistance to standard tyrosine kinase inhibitors.
Comprehensive molecular characterization improves patient risk stratification and is essential for identifying actionable targets and guiding selection of alternative targeted regimens.

Cite This Study

Klimczak et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec746b70b84ec8b9137b3 https://doi.org/10.1007/s11523-026-01249-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark